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1. Introduction 
Most of the drugs that are available in the marketplace are administered via the oral route, 
which is a convenient and cost effective route of administration (Lipinski 1995; Lipinski 
2000; Lipinski et al. 2001; Lipinski 2004; Abrahamsson and Lennernas 2005).  Thus, oral 
bioavailability is one of the key considerations for discovery and development of a new 
chemical entity (NCE). It is well recognized that poor oral bioavailability is one of the major 
causes of therapeutic variability, associated with the variable drug exposure (Beierle et al. 
1999; Bardelmeijer et al. 2000; Katsura and Inui 2003). This is particularly important for 
drugs with narrow therapeutic window or potential for resistance development such as 
antibiotics and cytotoxic drugs (Bardelmeijer et al. 2000). Hellriegel et al. reported a 
significant inverse relationship between the oral bioavailability of drugs from several 
therapeutic classes and the coefficient of inter-individual variability in their oral 
bioavailability (Hellriegel et al. 1996).  
Oral bioavailability is a product of fraction absorbed, fraction escaping gut-wall elimination, 
and fraction escaping hepatic elimination; and the factors that influence bioavailability can 
be divided into physiological, physicochemical, and biopharmaceutical factors. It has been 
well established that physicochemical properties determine oral absorption and drug 
metabolism. The “rule-of-five” devised by Lipinski and co-workers provided an important 
advance, with analysis of a large data set showing that compounds within certain 
physicochemical space tended to be more successful in clinical development than others. 
Using a dataset of 309 drugs, Varma et al. studied the interrelation of physicochemical 
properties and the individual parameters of oral absorption to define the physicochemical 
space for optimum human oral bioavailability (Varma et al. 2010). This analysis, which may 
provide a rational judgment on the physicochemical space to optimize oral bioavailability, 
will be discussed. Furthermore, the solubility and permeability as the fundamental 
properties of oral absorption will be discussed in-line with biopharmaceutics classification 
system. Uptake and efflux transporters are implicated as facilitating or limiting intestinal 
absorption. This book chapter will touch up on the latest findings on several chemistry 
approaches that has be directed to target the uptake transporters and circumvent the efflux 
transporters. Overall, this chapter will provides a better understanding of the interplay 
between gastrointestinal tract physiology/anatomy and drug physicochemical 
/biopharmaceutical factors in the absorption and metabolism mechanisms that affect oral 
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bioavailability humans; and enable a rational approach to design NCE with better 
absorption in humans.  
2. Concepts and theoretical calculations of oral bioavailability 
Bioavailability (F) is the extent to which an active moiety is absorbed from a pharmaceutical 
dosage form and becomes available in the systemic circulation (Thomas et al. 2006). 
Bioavailability is usually determined by calculating the respective plasma drug exposure 
assessed as the total area under the drug plasma concentration versus time curve (AUC) 
after oral and intravenous administration as: 
 oral IV
IV oral
AUC Dose
Absolute Bioavailability 
AUC Dose
= ×  (1) 
In general, determinants of oral drug bioavailability include fraction of dose absorbed in the 
gastrointestinal tract (GIT) and fraction of dose that escapes elimination by the intestinal 
tract, liver, and lung. Thus, oral bioavailability can be defined mathematically by the 
following equation:  
  abs g hF F F F= ⋅ ⋅   (2) 
Where Fabs is the fraction of the dose that is absorbed from the intestinal lumen to the 
intestinal enterocytes; Fg is the fraction of the dose that escapes pre-systemic intestinal first 
pass elimination; and Fh is the fraction of the dose that passes through the liver and escapes 
pre-systemic liver first-pass elimination. The fraction of the dose that escapes first-pass 
elimination across the intestine (Fg) and liver (Fh) can be estimated experimentally via the 
comparison of systemic exposures (AUC ratios) where the dosing routes are selected to 
isolate the contribution by a particular organ.  
Fg can be estimated (Eq. 3) for a compound when doses are given orally and via a 
cannulated hepatic portal vein (h.p.v.) with the fraction absorbed (Fabs) either assumed to be 
complete or is known.    
 h.p.voralabs g
h.p.v. oral
DoseAUC
F F
AUC Dose
⋅ = ×   (3) 
Similarly, Fh can be estimated for a compound when doses are given via a cannulated 
hepatic portal vein and intravenously (Eq. 4). 
 h.p.v. i.vh
i.v. h.p.v.
AUC Dose
F
AUC Dose
= ×    (4) 
The details on scientific background and factors that influence Fh are outside the scope of 
this book chapter; interested readers are encouraged to refer to our recent reviews in these 
areas (Thomas et al. 2006; Hurst et al. 2007; Varma et al. 2010) and other chapters in this 
book that focus on metabolism and related topics such as induction and inhibition of drug 
metabolism, pharmacogenetics and metabolism: past, present and future, and  effect of 
pharmaceutical excipients on drug metabolism.  
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3. Mechanism of oral absorption 
Following oral dosing, drug molecules can cross the luminal membrane through various 
mechanisms that involve passive diffusion or active transport. Passive diffusion is 
comprised of two pathways: the paracellular pathway, in which drug diffuses through the 
aqueous pores at the tight junctions between the intestinal enterocytes; and the transcellular 
(lipophilic) pathway, which requires drug diffusion across the lipid cell membrane of the 
enterocyte. The active transport pathway is mediated by transporters and is divided into 
active drug influx and efflux. It is important to note that the relevance of each route is 
determined by the compound’s physicochemical properties and its potential affinity for 
various transport proteins (Thomas et al. 2006; Hurst et al. 2007; Varma et al. 2010; Varma et 
al. 2010). 
3.1 Passive diffusion 
In paracellular diffusion, drug molecules are absorbed by diffusion and convective volume 
flow through the water-filled intercellular space (Lennernas 1995). In general, drugs that are 
absorbed through this pathway are small molecules (e.g., molecular weight [MW] < 250 
g/mol) and hydrophilic in nature (Log P < 0). Because the junctional complex has a net 
negative charge, positively charged molecules pass through more readily, whereas 
negatively charged molecules are repelled (Karlsson et al. 1999). Furthermore, the 
paracellular pathway offers a limited window for absorption since it accounts for < 0.01% of 
the total surface area of intestinal membrane. In addition, the tight junctions between cells 
become tighter traveling from the jejunum towards the colon.  
The transcellular pathway is the major route of absorption for most of drug molecules. In 
general, the rate of passive transcellular permeability is mainly determined by the rate of 
transport across the apical cell membrane, which is controlled by the physicochemical 
properties of the absorbed compound. Unlike the paracellular pathway, compounds that are 
absorbed through the transcellular pathway are unionised, with lipophilicity of Log P > 0 
and MW > 300 g/mole. In addition, the hydrogen-bonding capacity determined by the 
number of hydrogen bond donors and hydrogen bond acceptors is < 10 and 5, respectively 
(Lipinski 1995; Lipinski 2000; Avdeef 2001).  
3.2 Active transport 
Enterocytes express several transporters, belonging to the adenosine triphosphate (ATP) 
binding cassette (ABC) superfamily and the solute carrier (SLC) superfamilies, on the apical 
and basolateral membranes for the influx or efflux of endogenous substances and 
xenobiotics (Table 1). Although a variety of transporters are expressed in the enterocytes, 
only a few are known to play a key role in the intestinal absorption of drugs. ABC 
transporters utilize ATP to drive the transport and are called primary active transporter. 
However, SLC transporters majorly use the ion gradients (H+, Na+ and Ca++ gradients) 
created across the membrane by primary active carriers (Na+/K+-ATPase, Na+/H+-
ATPase) (Tsuji and Tamai 1996). ABC transporters expressed in the intestine include P-
glycoprotein (P-gp; ABCB1), breast cancer resistance protein (BCRP; ABCG2), multidrug 
resistance proteins (MRP1-6; ABCC1-6). P-gp, BCRP, MRP2 and MRP4 are localized on 
brush-border (apical) membrane while certain MRPs are expressed on the basolateral 
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membrane of the enterocytes. These efflux transporters functionally limit the enterocytic 
levels of their substrates by reducing uptake and facilitating efflux. SLC transporters 
suggested as relevant at the intestinal apical surface of epithelial cells include, peptide 
transporter (PepT1; SLC15A1), organic anion polypeptide transporters (OATP1A2, 
SLCO1A2; OATP2B1,SLCO2B1), monocarboxylate transporters (MCT1; SLC16A1), sodium-
multivitamin transport (SMVT; SLC5A6) and organic cation/zwitterion transporters 
(OCTN1, SLC22A4; OCTN2, SLC22A5). Several other SLC transporters including organic 
anion or cation transporters (OATs or OCTs; SLC22) have also been identified in the 
intestine, but seem to be of less importance in oral drug absorption (Englund et al. 2006; 
Seithel et al. 2006). 
 
Transporter protein Gene Orientation Drug Substrates 
P-gp/MDR1 ABCB1 Apical efflux Actinomycin D, cerivastatin, colchicine, 
cyclosporine A, daunorubicin, digoxin, docetaxel, 
doxorubicin, erythromycin, etoposide, 
fexofenadine, imatinib, indinavir, irinotecan, 
ivermectin, lapatinib, loperamide, losartan, 
nelfinavir, oseltamivir, paclitaxel, quinidine, 
ritonavir, saquinavir, sparfloxacin, tamoxifen, 
terfenadine, topotecan, verapamil, vinblastine, 
vincristine. 
BCRP ABCG2 Apical efflux Abacavir, ciprofloxacin, dantrolene,  
dipyridamole, enrofloxacin, erlotinib, etoposide, 
furosemide, gefitinib, genistein, glyburide, 
grepafloxacin, hydrochlorothiazide, imatinib, 
irinotecan, lamivudine, lapatinib, methotrexate, 
mitoxantrone, prazosin, rosuvastatin, tamoxifen, 
triamterene, zidovudine. 
MRP1 ABCC1 Basolateral 
efflux 
Daunorubicin, doxorubicin, epirubicin, 
grepafloxacin, methotrexate, vincristine. 
 
MRP2 ABCC2 Apical efflux Indinavir, methotrexate, ritonavir, saquinavir, 
vinblastine. 
MRP3 ABCC3 Basolateral 
efflux 
Etoposide, methotrexate. 
MRP4 ABCC4 Apical efflux Ceftizoxime, topotecan. 
 PepT1  SLC15A1 Apical uptake Ampicillin, bestatin, captoril, cephalexin, enalapril, 
fosinopril, oseltamivir, valciclovir. 
 
OATP 1A2 SLCO1A2 Apical uptake Fexofenadine, levofloxacin, methotrexate, ouabain, 
rosuvastatin, saquinavir. 
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Transporter protein Gene Orientation Drug Substrates 
OATP 2B1 SLCO2B1 Apical uptake Atorvastatin, bosentan, fluvastatin, glyburide, 
pitavastatin, pravastatin, montelukast, rosuvastatin. 
MCT1 SLC16A1 Apical uptake Arbaclofen placarbil, carindacillin, gabapentin 
enacarbil, ketoprofen, naproxen, phenethicillin, 
propicillin. 
SMVT SLC5A6 Apical uptake Gabapentin enacarbil 
OCTN1 SLC22A4 Apical uptake Quinidine, verapamil. 
OCTN2 SLC22A5 Apical uptake Cephaloridine, imatinib, ipratropium, tiotropium, 
quinidine, verapamil. 
CNT1 SLC28A1 Apical uptake Cytarabine, gemcitabine, zidovudine. 
CNT2 SLC28A2 Apical uptake Clofarabine, fluorouridine, ribavirin. 
ENT1 SLC29A1 Basolateral 
efflux 
Cladribine, clofarabine, cytarabine, gemcitabine, 
ribavirin. 
ENT2 SLC29A2 Basolateral 
efflux 
Clofarabine, gemcitabine, zidovudine. 
Table 1. Major human intestinal efflux and uptake transorters involved in drug transport. 
Gene, transport orientation and the clinical drug substrates of each transporter is included 
(Polli et al. 2001; Mahar Doan et al. 2002; Murakami and Takano 2008; Giacomini et al. 2010; 
Klaassen and Aleksunes 2010). 
4. Absorption kinetics 
When an active uptake process is involved, the overall transport of a drug across the 
intestinal enterocytes can be defined by model incorporating saturable and nonsaturable 
components (Eq. 5). 
  max,inf
,inf
D
m
J C
J K C
K C
⋅
= +
+
   (5) 
As outlined in the equation above, the total flux (J) of a compound across intestinal 
membrane is determined by four variables: Jmax, which is the maximal uptake rate, Km, which 
is the transporter substrate binding affinity, KD, which is the kinetic constant for 
nonsaturable transport, and C, which is the luminal drug concentration. The impact of 
intestinal transporters on the overall absorption of drug across the intestine is determined 
by the percentage component of the active process (JmaxC/(Km+C)) to the total flux, J, of the 
drug molecule. In general hydrophilic drug have low KD values and therefore there 
transport rates are mainly driven by the transporter activity, while for lipophilic drugs the 
passive component is usually high and the role of transporters is expected to be minimal.  
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5. Physiological, physicochemical and biopharmaceutical factors that impact 
oral drug absorption  
The factors that alter the rate and extent of oral drug absorption can be divided into three 
main categories: physiological, physicochemical and biopharmaceutical factors (Sabnis 1999; 
Horter and Dressman 2001; Kramer and Wunderli-Allenspach 2001; Zhou 2003; Pouton 
2006).  
5.1 Physiological factors that impact oral drug absorption  
5.1.1 Gastro-intestine anatomy and physiology 
In humans, the GIT consists mainly of the stomach, small intestine (the duodenum, jejunum, 
and ileum) and large intestine (cecum, colon and rectum). The total length of the human GIT 
is 8.35 m and the relative size of the human small intestine, which is considered the primary 
site of drug absorption, to the total length of the GI tract is 81%. As for the large intestine, its 
relative size in humans is 19%. It may also be pointed out that the cecum, which is the major 
site of microbial digestion, forms only 5% of the length of the human large intestine 
(DeSesso and Jacobson 2001). 
The surface area is attributed to the fact that the human small intestine has three anatomical 
modifications that significantly increase the surface area of the human small intestine 
(Shargel and Yu 1999). The human small intestine has grossly observable folds of mucosa 
(plicae circularis or folds of kerckring) that increase the surface area threefold. From the 
plicae circularis, microscopic finger-like pieces of tissue called villi project, which increase 
the surface area by 10-fold for humans. Each villus is covered in microvilli, which increase 
the surface area by 20-fold. Unlike the small intestine, the large intestine surface area does 
not have villi and is divided into geographical areas by transverse furrows. In addition, the 
large intestine enterocytes differ slightly from that of the small intestine and its microvilli 
are less packed (Kararli 1995). Overall, this significantly contributes to the smaller surface 
area of the large intestine in humans and is consistent with the fact that small intestine is the 
major site of drug absorption in humans. 
5.1.2 Unstirred water layer 
Adjacent to the intestinal membrane is an unstirred water layer, which is a potential barrier 
for the absorption of various drug molecules across the intestinal membrane (Winne 1976; 
Hayton 1980). The thickness of this layer in humans is only 25 μm (Strocchi et al. 1996). 
Chiou et al. quantitatively studied the impact of the unstirred water layer adjacent to the 
intestinal membrane on the rate and extent of absorption of passively absorbed drugs with 
different membrane absorption half-lives (10 – 300 min) in humans (Chiou 1994). Results of 
this analysis suggested that the presence of the unstirred water layer is generally expected to 
have a relatively mild or insignificant effect on the rate of absorption and an insignificant 
effect on the extent of absorption (Kimura and Higaki 2002). 
5.1.3 Gastrointestinal transit times 
The absorption rate of a drug molecule is generally a function of drug absorption through 
the GIT, which is determined by the residence time and absorption in each GIT segment 
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(Kimura and Higaki 2002). In general, gastric transit time impacts the systemic exposure of 
rapidly dissolved and well absorbed drugs. However, intestinal transit time influences the 
absorption of drugs with limited mucosal permeability, carrier mediated uptake, drugs 
subject to intestinal degradation, or products whose dissolution is the rate limiting step for 
systemic absorption (Martinez and Amidon 2002). In contrast to gastric transit time, 
intestinal transit time is independent of the feeding conditions and the physical composition 
of the intestinal contents (Garanero et al. 2005) . The human intestinal transit time is ~3 – 4 h 
(DeSesso and Jacobson 2001; Kimura and Higaki 2002). Several studies suggested that in 
human small intestine, there is a gradient of velocity where the small intestinal transit in the 
proximal intestine was faster compared with the distal intestine. The transit time in human 
large intestine can vary in the range of 8 – 72 h (DeSesso and Jacobson 2001). 
5.1.4 The GIT pH 
The extent of ionization plays a pivotal role in determining the drug dissolution rate and 
passive permeability across the GIT. Therefore, it becomes clear that the pH at the 
absorption site is a critical factor in facilitating or inhibiting the dissolution and absorption 
of various ionizable drug molecules (DeSesso and Jacobson 2001). It should be stressed that 
the pH of the luminal content (chyme) is altered by the luminal secretions. The pH of chyme 
is acidic and can be as low as 2.3. When the chyme arrives in the duodenum, it is quickly 
neutralized by the secretion of the pancreatic bicarbonate and bile. The pH values of chyme 
become progressively more alkaline in the distal portion of the small intestine in humans. 
However, the pH of chyme in the large intestine is generally more acidic than the pH 
observed in the small intestine in humans, possibly due to the fermentation mediated by the 
microbial flora (Kararli 1995). 
5.1.5 Bile fluid 
Bile is produced by hepatocytes and drained through the many bile ducts that penetrate the 
liver (DeSesso and Jacobson 2001). During this process, the epithelial cells add a watery 
solution that is rich in bicarbonates which increases the alkalinity of the solution. In humans, 
the bile is stored and concentrated up to five times its original potency in the gall bladder. It 
is to be noted that the human gall bladder secrets bile at a rate of 2 – 22 ml/kg/day. In 
humans, bile acts as a detergent to emulsify fats by increasing the surface area to help 
enzyme action, and thus aid in their absorption in the small intestine. In addition to 
bicarbonate solution, bile is composed of bile salts, such as the salts of taurocholic acid and 
deoxycholic acid, which are combined with phospholipids to break down fat globules in the 
process of emulsification by associating their hydrophobic side with lipids and the 
hydrophilic side with water. Emulsified droplets are then organized into many micelles 
which increases their absorption. Because bile increases the absorption of fats, it also plays a 
pivotal role in the absorption of the fat-soluble vitamins and steroids (Hanano 1993; 
Kirilenko and Gregoriadis 1993).  
5.1.6 Bacterial microflora 
In humans, bacterial microflora exists in most of the GIT and become an important component 
of the luminal content. However, there is no bacterial microflora in the stomach and upper 
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small intestine. This is mainly attributed to the low pH of the human gastric content. However, 
a large number of bacterial microflora populates the human’s distal small and large intestines 
(Cummings and Macfarlane 1997). These bacterial microflora play a role in the metabolism of 
various chemicals and xenobiotics through hydrolysis, dehydroxylation, deamidation, 
decarboxylation and reduction of azide groups (Lichtenstein 1990; Cummings and Macfarlane 
1997; Blaut et al. 2003). Among these reactions, hydrolysis of the glucuronide conjugates is the 
most important metabolic reaction that is mediated by the glucronidase enzyme and produced 
by the bacterial microflora found in the GIT of humans.  
5.1.7 Lymphatic absorption 
The intestinal lymphatic route plays a key role in the absorption of drugs that are highly 
lipophilic. It has many advantages, such as increase in the oral bioavailability of highly 
lipophilic drugs by avoiding hepatic first pass effect, direct targeting of lymphoid tissue, 
indirect targeting of specific sites associated with low-density lipoprotein receptors, and 
alteration in the rate of oral drug input to the systemic circulation thereby providing 
opportunity for controlled release drug formulation (Cheema et al. 1987; Trevaskis et al. 
2005; Trevaskis et al. 2006; Trevaskis et al. 2006).  
5.1.8 Intestinal drug transporters 
P-glycoprotein (P-gp) 
P-gp (MDR1; ABCB1), an ATP-dependent transmembrane efflux pump belonging to ABC 
superfamily, shows affinity to a wide variety of structurally unrelated compounds (Juliano 
and Ling 1976). It is expressed as a 1280 amino acid long (MW ~170 kDa) single chain 
glycoprotein with two homologous portions of equal length, each containing six 
transmembrane (TM) domains and two ATP binding regions separated by a flexible linker 
polypeptide region (Schinkel et al. 1993; Ambudkar et al. 1999).  
Immunohistochemical analysis using monoclonal antibody provided evidence for 
localization of P-gp in a wide range of tissues, particularly in columnar epithelial cells of the 
lower GIT, capillary endothelial cells of brain and testis, canalicular surface of hepatocytes 
and apical surface of proximal tubule in kidney (Thiebut et al. 1987). Due to selective 
distribution at the port of drug entry and exit, P-gp has been speculated to play a major 
physiological role in the absorption, distribution and excretion of xenobiotics and 
endogenous substrates. Overall, P-gp functions as a biochemical barrier for entry of drugs 
across intestine and brain, as well as a vacuum cleaner to expel drugs from the intestine, 
liver, kidney, etc. A number of clinically important drugs are P-gp substrates (Table 1), 
which are as diverse as anthracyclines (doxorubicin, daunorubicin), alkaloids (reserpine, 
vincristine, vinblastine), specific peptides (valinomycin, cyclosporine), steroid hormones 
(aldosterone, hydrocortisone) and local anesthetics (dibucaine) (Polli et al. 2001; Mahar 
Doan et al. 2002; Varma et al. 2003; Takano et al. 2006). P-gp substrates, digoxin and 
talinolol, show pharmacokinetic changes in human upon coadministration with P-gp 
inhibitors (Gramatte et al. 1996; Fenner et al. 2009). Greiner et al., studied the effect of 
rifampicin pretreatment on the oral pharmacokinetics of digoxin and suggested that 
rifampicn induced duodenal P-gp expression and thus significantly reduced AUC of 
digoxin (Greiner et al. 1999). Similarly, rifampicn decreased talinolol oral exposure, which is 
consistent with ~4 fold increase in duodenal P-gp expression (Westphal et al. 2000). 
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P-gp affinity screening using various in vitro culture models is now an integral part of drug 
discovery due to wide substrate specificity and clinical relevance in drug disposition and 
associated drug-drug interactions (DDIs) (Varma et al. 2004a). Tailoring of molecules to 
reduce substrate specificity to P-gp may help in improving the oral bioavailability of drugs. 
Seelig and coworkers suggested that the partitioning into the lipid membrane is the rate-
limiting step for the interaction of a substrate with P-gp and that dissociation of the P-gp-
substrate complex is determined by the number and strength of the hydrogen bonds formed 
between the substrate and the transporter (Seelig and Landwojtowicz 2000). Several studies 
have related the binding affinity (Km) of P-gp for substrates and modulators to their lipid-
water partition coefficient (Log P). Evidence suggests that a drug with high Log P will 
accumulate to a high concentration within the cytoplasmic membrane and favors binding to 
P-gp with low Km value, while a drug with low partitioning will have a lower membrane 
concentration and a high Km value. Three-dimensional structures of a large number of drugs 
revealed that the minimal common binding element consisting of two or three hydrogen 
bond acceptor (HBA) groups in a specific spatial distance. Since the TM sequences of P-gp 
are rich in hydrogen bond donor (HBD) groups, it is hypothesized that P-gp recognizes the 
HBA groups of the substrates through hydrogen bond formation in the lipid membrane 
environment (Seelig 1998; Seelig 1998). Didziapetris et al.  studied 220 substrates and 1000 
non-substrates and proposed the ‘rule of four’, which states that compounds with the HBA 
≥ 8, a molecular weight (MW) > 400 g/mol and most acidic pKa < 4 are likely to be P-gp 
substrates, while compounds with HBA ≤ 4, MW < 400 g/mol and most basic pKa > 8 are 
not substrates to P-gp (Didziapetris et al. 2003). Although many such models describe the 
physicochemical attributes of P-gp interaction and are shown to have high predictability, 
existence of multiple binding sites and other complicating factors has prevented the 
development of a definitive SAR (Stouch and Gudmundsson 2002).  
Breast Cancer Resistance Protein (BCRP) 
BCRP (ABCP/MXR; ABCG2), a member of the ABC family of transporters, is considered a 
half-transporter with six TM domains and one ATP-binding domain at the amino terminus 
and is believed to homodimerize in order to function (Staud and Pavek 2005). It is composed 
of 655 amino acids with a MW of 72 kDa (Graf et al. 2003). An atomic model of BCRP was 
predicted by homology modeling based on the crystal structure of the bacterial multidrug 
exporter Sav1866, which suggested that BCRP had multiple drug binding sites (Hazai and 
Bikadi 2008; Muenster et al. 2008). BCRP expression can be traced to placenta, kidney, liver, 
testis, brain, mammary tissue, and intestine (Doyle and Ross 2003). Unlike P-gp, the 
expression of BCRP along the length of the small intestine does not vary significantly 
(Bruyere et al. 2010). Additionally, the mRNA level of BCRP is notably higher than other 
efflux transporters such as P-gp and MRP2 in the human intestine (Taipalensuu et al. 2001). 
Since BCRP is highly expressed on the apical membrane of enterocytes and effluxing 
substrates back into the lumen, it has been noted to play an important role as a 
detoxification efflux transporter and limiting drug absorption in the GIT (Zaher et al. 2006).  
BCRP exhibits broad substrate specificity and accepts diverse chemical space, as do other 
ABC transporters. Substrates to BCRP include (Table 1): chemotherapy agents 
(mitoxantrone, camptothecins, tyrosine kinase inhibitors), antivirals (zidovudine, 
lamivudine), HMG-CoA reductase inhibitors (statins), benzimidazoles, and antibiotics 
(ciprofloxacin, rifampicin) (Bailey et al. ; Merino et al. 2005; Huang et al. 2006; Takano et al. 
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2006; Ando et al. 2007; Dauchy et al. 2009; Ieiri et al. 2009). Some of the BCRP substrates are 
also effectively effluxed by P-gp. For example, etoposide, irinotecan and tamoxifen are 
substrates for both BCRP and P-gp (Table 1). In a clinical study, Kruijtzer et al.  showed an 
increase in bioavailability of topotecan from 40% to 97% in the presence of GF120918, a 
potent inhibitor of BCRP and P-gp (Kruijtzer et al. 2002). Yamasaki et al. investigated the 
impact of genetic polymorphisms of ABCG2 (421c>A) and NAT2 on the pharmacokinetics 
of sulfasalazine, in 37 healthy volunteers and suggested sulfasalazine as a useful probe 
substrate for evaluating the role of BCRP in the intestinal disposition (Yamasaki et al. 2008). 
BCRP polymorphism significantly affects the pharmacokinetics of several HMG-CoA 
reductase inhibitors, including atrovastatin, rosuvastatin, fluvastatin and simvastatin 
lactone, but has no significant effect on pravastatin or simvastatin acid (Bailey et al. ; Huang 
et al. 2006; Ieiri et al. 2009; Keskitalo et al. 2009; Keskitalo et al. 2009). For example, 
rosuvastatin AUC was 100% and 144% greater in the c.421AA genotype population than in 
those with c.421CA and the c.421CC genotypes, respectively. Although, few clinical studies 
have been reported on the role of BCRP in the intestinal absorption, several studies using 
BCRP knock-out mice suggest significant impact (Merino et al. 2006; Seamon et al. 2006; 
Zaher et al. 2006; Yamagata et al. 2007).  
Due to general selectivity, substrates of BCRP can be either negatively or positively charged, 
hydrophobic or hydrophilic, and unconjugated or conjugated. Several attempts were made 
to establish SAR for BCRP interaction, however, many analysis methods were based on the 
datasets of inhibitors (Saito et al. 2006; Matsson et al. 2007; Matsson et al. 2009; Nicolle et al. 
2009). Yoshikawa et al.  studied BCRP substrate specificity of 14 camptothecin (CPT) 
analogues, and noted that CPT analogues that showed ATP-dependent transport in BCRP-
overexpressing membrane vesicles possess one –hydroxy or –amino group (Yoshikawa et al. 
2004). Also CPT analogues showed a good correlation between polarity and BCRP-
association, where highly polar compounds showed substrate specificity. It is likely that the 
presence of hydroxyl and amino functional groups facilitate hydrogen bonding with the 
amino acid residues at the binding site of BCRP. Furthermore, presence of a negative 
electrostatic potential area at position 10 for SN-38 and SN-398, but not in SN-22, suggests 
that CPT analogues with this feature are potential substrates for BCRP (Nakagawa et al. 
2006). BCRP substrate specificity of a set of pyrrolobenzodiazepine (PBD) derivatives 
showed a good correlation with the electrostatic potential and aromaticity (Kaliszczak et al. 
2010). PBDs with a greater number of HBA and the electronegativity and aromaticity of the 
C2 substitution show affinity to BCRP. Evidently, BCRP-mediated efflux could be 
circumvented by limiting C2 aryl substituents and the number of aromatic rings. In general, 
BCRP substrates share a same set of molecular properties as that of substrates to P-gp and 
other efflux pumps (Begley 2004; Kunta and Sinko 2004; Takano et al. 2006). 
Peptide transporter 1 (Pept1) 
PepT1  (SLC15A1), an electrogenic, H+-dependent transporter, was first cloned from the 
rabbit intestine and subsequently from both rat and human (Fei et al. 1994). The cloned 
human PepT1 cDNA sequence encodes a 708 amino acid protein (MW 79 kDa) with an 
isoelectric point of 8.6 and several putative glycosylation and phosphorylation sites. There 
are 12 putative α-helical TM domains and a large extracellular loop between the IX and X 
TM domains, which possess intacellularly localized N- and C- termini (Liang et al. 1995; 
Rubio-Aliaga and Daniel 2008). Herrera-Ruiz et al. reported that PepT1 appears to be 
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localized predominantly in the duodenum, with decreasing expression in the jejunum and 
ileum (Herrera-Ruiz et al. 2001).   
PepT1 has been shown to be independent of Na+ and uses H+-gradient and inside-negative 
membrane potential to provide the necessary driving force for substrate translocation. At 
the brush border membrane of enterocytes, an in-ward proton gradient is generated through 
the activity of an electroneutral proton/cation exchanger, Na+/H+ antiporter. This enables 
the uptake of  PepT1  transporter substrates to be coupled with the influx of protons back 
into the enterocytes (Adibi 1997). The uptake of the PepT1 substrates is strongly dependent 
on the extracellular pH, where a pH of 4.5-6.5 (depending on the net charge of the 
substrate), is needed for optimal transport activity. Irie et al. investigated the transport 
mechanism of PepT1 for neutral and charged substrates by experimental studies and 
computational simulation (Irie et al. 2005). These uptake studies suggested that the Km of 
glycylsarcosine (Gly-Sar), a neutral substrate, decreased as the pH dropped from 7.4 to 5.5, yet 
increased at a pH of 5.0. The Km value of an anionic substrate, ceftibuten, declined steadily 
with a decreasing pH. Furthermore, the maximum transporter rate (Vmax) values gradually 
increased with a fall in pH from 7.4 to 5.0, for both substrates. Consequently, the group 
hypothesized that unlike neutral and cationic substrates, negatively charged molecules not 
only require H+ binding to H+-binding site, but also to the substrate-binding site. 
The 3D structure of the substrate binding site of PepT1  is not yet known, but its template 
has been proposed by the large variety of substrates (Foley et al. ; Meredith and Price 2006). 
It is interesting to note that the peptide bond is not required for substrate binding specificity 
of  PepT1  transporter (Brandsch et al. 2004). Only the two oppositely charged free head 
groups (carboxylic carbon and amino nitrogen) separated by a 4 spacer carbon unit were 
identified as a minimal structural feature requirement (Doring et al. 1998). In the presence of 
a peptide bond, it is only the backbone carbonyl that is functional. This minimal 
configuration also explains the efficient transport of δ-aminolevulinic acid, which serves as a 
precursor for the endogenous porphyrin accumulation on which photodynamic therapy of 
tumors is based. In addition, the side chains provided in both di and tripeptides and in 
xenobiotics with charge polarity and conformation are pivotal in determining the binding 
affinities. It should also be emphasized that for the di and tripeptides, only the trans-
configuration of the peptide bond is transported. Besides a preferred free N-terminal amino 
group, a high electron density around the terminal carboxylic group in dipeptide, or 
alternatively around the carbonyl group of the second amino acid in a tripeptide structure, 
is needed to ensure optimum binding affinity. Furthermore, high electron densities at the 
first and third side chains, as well as the presence of hydrophobic side chains, significantly 
contribute to overall binding affinity (Brandsch et al. 1999). 
PepT1 is a low-affinity (Km of 200 µM to 15 mM), high-capacity transporter and is known to 
play a pivotal role in the absorption and distribution of peptidomimetics that include ǃ-
lactam antibiotics  such as cephalosporins and penicillins, angiotensin converting enzyme 
inhibitor such as zofenopril, fosinopril, benazepril, quinapril, trandolapril, spirapril, 
cilazapril, ramipril, moexipril, quinaprilat, and perindopril., selected rennin inhibitors, 
antitumor agents such as bestatin, and dopamine receptor antagonists such as sulpiride 
(Terada et al. 1997; Bretschneider et al. 1999; Watanabe et al. 2002; Watanabe et al. 2002; 
Watanabe et al. 2004; Knutter et al. 2008). Using PepT1 as an intestinal transporter to 
increase oral exposure of compounds with low oral bioavailability was shown to be an 
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effective strategy (Kikuchi et al. 2009). For example, acyclovir is usually associated with 
suboptimal oral plasma exposure (oral bioavailability 15%) that can lead to resistant viral 
strains. To overcome this limitation, valacyclovir, a L-valine ester prodrug of acyclovir was 
effectively designed to increase the oral absorption and plasma exposure of acyclovir 
(Ganapathy et al. 1998).  
Organic Anion-Transporting Polypeptides (OATPS) 
OATPs (SLCO) are transmembrane solute carriers that mediate the proton-dependent 
transport of a wide range of amphipathic endogenous and exogenous organic compounds 
across the plasma membrane. Currently, 39 members of the OATP/SLCO superfamily have 
been identified in mammalian species (Hagenbuch and Meier 2004). The OATPs represent 
integral membrane proteins that contain 12 TM domains where amino and carboxy termini 
are oriented to the cytoplasmic spaces. There is limited information regarding the tertiary 
structures of OATPs, although more recent studies are beginning to address this aspect. In 
this book chapter , we focus on OATP2B1 (SLCO2B1) and OATP1A2 (SLCO1A2). OATP2B1 
plays a key role in the uptake of various xenobiotics and was originally isolated from the 
human brain and named OATP-B (Tamai et al. 2000; Kullak-Ublick et al. 2001) or SLC21A9 
(Hagenbuch and Meier 2003). OATP2B1 mRNA is expressed in the human small intestine 
(Tamai et al. 2000; Kullak-Ublick et al. 2001; Sai et al. 2006) and its protein is 
immunolocalised at the apical surface of human small intestine  (Kobayashi et al. 2003) and 
Caco-2 cell monolayers (Sai et al. 2006).  
Similar to other OATPs, transport via OATP2B1 is generally considered to occur in a 
bidirectional fashion driven by the solute concentration gradient across the membrane. 
Heterologous expression of OATP2B1 produces a Na+-independent, pH-gradient dependent 
transporter with a relatively narrow substrate specificity compared to other OATPs 
(Nozawa et al. 2004). Extracellular acidification promoted solute uptake, a property of 
OATP2B1 that bears relevance to the small intestinal environment in which the transporter 
is expressed on the apical membrane of the enterocytes. Kobayashi et al. studied the impact 
of pH on the uptake of both estrone-3-sulfate and pravastatin in OATP-2B1 transfected HEK 
293 cells. The group reported that the uptake of both compounds were pH dependent, 
where higher uptake at pH 5.5 relative to that at 7.4 pH was reported. It is interesting to note 
that an increase was only observed in Vmax with a decrease of pH from 7.4 to 5.0 and a 
negligible change was observed in Km at studied pH (Kobayashi et al. 2003).  In a recent 
study, our group examined the role of OATP2B1 in the intestinal absorption and tissue 
uptake of 3-hydroxy-3-methylglutaryl-CoenzymeA (HMG-CoA) reductase inhibitors 
(statins) (Varma et al. Accepted). We first investigated impact of extracellular pH on the 
functional affinity of statins to the transporter using OATP2B1-transfeced HEK293 cells. The 
results indicated that OATP2B1-mediated transport is significant for rosuvastatin, 
fluvastatin and atorvastatin, at neutral pH. However, OATP2B1 showed broader substrate 
specificity as well as enhanced transporter activity at acidic pH consistent with other 
research groups’ findings (Kobayashi et al. 2003). Furthermore, uptake at acidic pH was 
diminished in the presence of proton ionophore, suggesting proton-gradient as the driving 
force for OATP2B1 activity. Notably, passive transport rates are predominant or comparable 
to active transport rates for statins, except for rosuvastatin and fluvastatin. Second, we 
studied the effect of OATP modulators on statins uptake. At pH 6.0, OATP2B1-mediated 
transport of atorvastatin and cerivastatin was not inhibitable, while rosuvastatin transport 
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was inhibited by E-3-S, rifamycin SV and cyclosporine with IC50 values of 19.7±3.3μM, 
0.53±0.2μM and 2.2±0.4μM, respectively. Rifamycin SV inhibited OATP2B1-mediated 
transport of E-3-S and rosuvastatin with similar IC50 values at pH 6.0 and 7.4, suggesting 
that the inhibitor affinity is not pH-dependent. Finally, we noted that OATP2B1-mediated 
transport of E-3-S, but not rosuvastatin, is pH-sensitive in intestinal epithelial (Caco-2) cells. 
However, uptake of E-3-S and rosuvastatin by Caco-2 cells was diminished in the presence 
of proton ionophore (FCCP). The present results indicate that OATP2B1 may be involved in 
the tissue uptake of rosuvastatin and fluvastatin, while OATP2B1 may play a significant role 
in the intestinal absorption of several statins due to their transporter affinity at acidic pH.  
The physiological and pharmacological role played by OATP2B1 in intestinal absorption 
may also vary between individuals. For example, a single nucleotide polymorphism (SNP) 
(found in 31% of the Japanese population investigated within the referenced study) leads to 
an amino acid change in the OATP2B1 protein (S486F), which is associated with a greater 
than 50% reduction in transport capacity (Nozawa et al. 2002). 
Since the unavailability of crystal structures of OATPs and relative difficulties in validating 
their homology models, pharmacophore models have helped elucidate the key molecular 
features involved in the substrate/inhibitor and protein interactions. These models have 
demonstrated good structure and activity correlation within the studied chemical space.  
The proposed OATP2B1 pharmacophores may share the similar molecular features for the 
consideration of the substrate binding at the positively-charged region. Its substrates may 
have features such as a hydrophobic core to form the π-stacking interaction with the 
imidazole ring of H579, or a HBD to directly interact with the nitrogen atom of the 
imidazole ring, both of which should be oriented at the energetically favored position inside 
the pore. To model these interactions structurally using molecular docking and dynamics, 
the minimal requirement will be a validated homology model of OATP2B1. To date, the 
strategy to elucidate the SAR of OATP2B1 is the combination of QSAR, pharmacophore, and 
structure-based modeling with the support of in vitro and cell-based experimental data.    
Another OATP transporter that plays a role in the intestinal absorption of xenobiotics is 
OATP1A2 (also known as human OATP-A or SLCO1A2). This transporter consists of 670 
amino acids and  is expressed in the brain, kidney and apical membrane of the enterocytes 
(Kullak-Ublick et al. 1995). Unlike other OATP transporters, OATP1A2 possesses perhaps 
the broadest spectrum of solutes in that compounds of acidic, basic, and neutral character 
are substrates. It has been reported to transport bile salts and bromosulfophtalein (BSP), 
steroid sulfates, thyroid hormones [triiodothyronine (T3), thyroxine (T4), and reverse T3], 
prostaglandin E2, fexofenadine, opioid peptides [e.g., deltorphin II and (d-
penicillamine)enkephalin], rocuronium, N-methylquinine and N-methylquinidine, ouabain, 
the endothelin receptor antagonist BQ-123, talinolol, and the thrombin inhibitor CRC-220 
(Ianculescu et al. ; Loubiere et al. ; Kullak-Ublick et al. 1995; Hsiang et al. 1999; Gao et al. 
2000; Geyer et al. 2004; Schwarz et al. 2005; Shimizu et al. 2005; Kalliokoski and Niemi 2009). 
Similar to OATP2B1, genetic variations has been reported in SLCO1A2. For example, Lee et 
al. identified six non-synonymous SNPs in the coding region of SLCO1A2. The c.516A>C 
(p.Glu172Asp) variant had markedly reduced uptake capacity for the OATP1A2 substrates 
estrone 3-sulfate and the d-opioid receptor agonists, deltorphin II and [D-penicillamine2,5]-
enkephalin in vitro. The group concluded that considering its substrate specificity and 
expression in organs such as the brain, kidney and intestine, genetic variations in SLCO1A2 
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may be an important contributor to inter-individual variability in drug disposition and 
central nervous system entry of OATP1A2 substrate drugs (Lee et al. 2005). 
In the clinic, the effect of grapefruit juice on the oral exposure of fexofendadine was 
evaluated. The oral plasma exposure of fexofenadine was decreased 63%. This seems likely 
to be mediated by inhibition of intestinal absorption via OATP1A2. (Dresser et al. 2005; 
Bailey et al. 2007). Similar findings were reported in a study that evaluated the effect of 
single and repeated grapefruit juice ingenstion on the oral plasma exposure of talinolol in 
humans. The decrease in the oral plasma exposure of talinolol (44%) was attributed to the 
inhibition of OATP1A2 (Shirasaka et al.; Schwarz et al. 2005). Overall, these findings identify 
OATP1A2 as a potential site for diet-drug interactions and clearly demonstrate the potential 
role of OATP1A2 in the absorption of xenobiotics. 
Monocarboxylate transporter 1 (MCT1) 
The bi-directional movement of monocarboxylic acids across the plasma membrane is 
catalyzed by a family of proton-linked monocarboxylate transporters (MCTs). MCTs are 
encoded by the SLC16A gene family, of which there are 14 known members that were 
identified through screening genomic and expressed sequence tag databases (Halestrap and 
Meredith 2004).  Only MCTs 1-4 have been shown to catalyze the proton-coupled transport 
of metabolically important monocarboxylates such as lactate and pyruvate (Halestrap and 
Meredith 2004). This book chapter  will focus on the first member of the MCT family, MCT1 
(SLC16A1), which is well characterized and known to play a role in the intestinal drug 
absorption. 
MCT1 consists of 12 TM ǂ-helical domains with a large intracellular loop between TM 
segments VI and VII and intracellular C- and N- termini (Poole et al. 1996; Halestrap and 
Price 1999). MCT1 is expressed in most tissues and is especially prominent in the heart, red 
skeletal muscle, erythrocytes, and all cells under hypoxic conditions, where it can either be 
involved in the uptake or efflux of glycolytically produced lactic acid. MCT1 is also highly 
expressed in the small and large intestine (Gill et al. 2005), where it is responsible for the 
absorption of short chain fatty acids such as acetate, propionate and butyrate, produced 
from microbial fermentation of dietary fiber (Cummings and Macfarlane 1991).  
MCT1 catalyses the facilitative diffusion of substrate across the plasma membrane, coupled 
with the translocation of a proton. The driving force for transport is provided by both the 
substrate and H+-concentration gradients, with the pH gradient determining the extent of 
transport activity (Juel 1997; Halestrap and Price 1999). Based on the reported crystal 
structures of two members of the major facilitator superfamily, the Escherischia coli 
glycerol-3-phosphate transporter (G1pT) and lactose permease (Lac Y) (Abramson et al. 
2003; Huang et al. 2003), the structure of MCT1 has been modelled (Manoharan et al. 2006). 
Futhermore, site-directed mutagenesis identifying key substrate-binding residues together 
with structural modeling has lead to the suggestion of a translocation cycle as the 
mechanism of transport for MCT1 (Wilson et al. 2009). This mechanism of transport is 
consistent with the “Rocker Switch” mechanism (Law et al. 2008). This model describes 
MCT1 existing in an open and closed conformation, with the N- and C-terminal halves 
tilting against each other along an axis that separates the two domains, allowing the 
substrate binding site alternating access to the either side of the membrane (Wilson et al. 
2009). MCT1 also requires an ancillary protein, CD147, for correct trafficking to the plasma 
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membrane as well as functional activity (Wilson et al. 2005). CD147 is a member of the 
immunoglobulin gene superfamily, and has been shown to closely interact with both MCT1 
and MCT4 (Kirk et al. 2000). 
MCT1 is a low affinity, high capacity transporter that has been shown to transport 
unbranched aliphatic monocarboxylates such as acetate and proprionate and substituted 
monocarboxylates pyruvate, lactate, acetoacetate and ǃ-hydroxybutyrate, with the Km 
values for pyruvate and lactate about 0.7 and 3-5 mM, respectively (Halestrap and Meredith 
2004). Other MCT1 monocarboxylate substrates include the branched chain keto-acids 
(formed from the transamination of leucine, isoleucine and valine) and the ketone bodies 
acetoacetate, ǃ-hydroxybutyrate and acetate (Poole and Halestrap 1993), and exogenous 
acids p-aminohippuric acid, benzoic acid, Ǆ-hydroxy butyrate, foscarnet, mevolonic acid, 
and salicylic acid (Enerson and Drewes 2003; Lam et al. 2010). MCT1 is also thought to be 
responsible for the intestinal absorption of the ǃ-lactam antibiotics such as carbenicillin 
indanyl sodium as well as phenethicillin and propicillin (Li et al. 1999). The targeting of 
MCT1 by pharmacologically active drugs has been shown to result in enhanced intestinal 
drug uptake. For example, XP13512 is rapidly absorbed along the length of the intestine via 
MCT1 (as well as the SMVT). XP13512 is an anionic compound produced by the reversible 
modification of the amine group of gabapentin (which has limited oral absorption), with an 
acyloxyalkylcarbamate promoeity (Cundy et al. 2004). Overall, prototypical substrates of 
MCT1 generally consist of weak organic acids with the carboxyl group attached to a relatively 
small R group containing lipophilic or hydrophilic properties (Enerson and Drewes 2003). 
5.2 Physicochemical factors that impact oral drug absorption  
Our group recently investigated the interrelation of physicochemical properties and 
individual parameters for a database comprised of Fa, Fg, Fh, and F values for 309 drugs in 
humans (Varma et al. 2010). The aim is to define the physicochemical space for optimum 
human oral bioavailability. The current data set suggested an even distribution of the 
bioavailability values, with about 17% of compounds showing F less than 0.2 and 34% of 
compounds showing F more than 0.8. However, the vast majority of compounds showed Fa 
(71%), Fg (70%), and Fh (73%) more than 0.8. The current data set indicated that 
bioavailability is mainly limited by absorption as evident from the subset of compounds 
showing bioavailability less than 0.2, where mean and median values suggest the rank-order 
of limiting parameters as Fa > Fg > Fh.  
The distribution of the data set in physicochemical space is heterogeneous and thoroughly 
covered the range of conventional small molecule marketed drugs. Trend analysis clearly 
indicate that ionization state, molecular weight (MW), lipophilicity, polar descriptors, and 
free rotatable bonds (RB) influence bioavailability. For example, ionization state analysis of 
compounds studied indicate that although bases tend to have higher Fa, they are relatively 
less bioavailable as compared to acids and neutrals. MW trends suggest that increasing the 
size of molecules above 400 g/mol will on average lead to a steady decline in bioavailability, 
mainly due to the effect on Fa. Lipophilicity (cLog P and cLog D pH7.4) trends indicate that 
very hydrophilic compounds have drastically reduced intestinal absorption. On the other 
hands, RB and polar descriptors such as PSA, hydrogen bonding count (HBA + HBD) 
showed inverse relationship with Fa, in particular for compounds with RB > 12, PSA greater 
than 125 A°2, and hydrogen bond count more than 9.  
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The scholarship outlined above is consistent with the finding of Lipinski et al, who 
introduced the rule of 5 (RO5), which is one of the most widely used concepts to 
qualitatively predict oral drug absorption. The group analyzed 2245 compounds from the 
World Drug Index (WDI) database that were either considered for, or entered into, Phase II 
clinical trials. Results indicate that good oral absorption is more likely with drug molecules 
that have less than 5 hydrogen bond donors (defined as NH or OH groups)/10 hydrogen 
bond acceptors (defined as oxygen or nitrogen atoms, including those that are part of 
hydrogen-bond donors), a molecular weight that is smaller than 500, and a calculated 
lipophilicity (cLog P) that is smaller than 5 (Lipinski 1995; Lipinski 2000; Lipinski et al. 
2001). Poor bioavailability is more likely when the compounds violate two or more of the 
RO5. Using the current data set, we evaluated the relationships between number of 
violations and bioavailability and the individual processes. From Figure 1, it is evident that 
median bioavailability dropped considerably from 0.70 to 0.35 (p < 0.005) for the compound 
subsets with no violation and two violations, respectively. Compounds with three violations 
showed a further decline in median bioavailability (0.05). However, similar relationship was 
observed only with Fa but not with Fg and Fh, suggesting that relationship of rule-of-five 
and bioavailability is associated mainly with intestinal absorption.  
5.3 Biopharmaceutical factors that impact oral drug absorption 
5.3.1 Particle size 
Drug dissolution rate is an important parameter that affects oral drug absorption (Chaumeil 
1998; Boobis et al. 2002; Hilgers et al. 2003). A drug is defined as being poorly soluble when 
its dissolution rate is so slow that dissolution takes longer than the transit time past its 
absorptive sites, resulting in incomplete oral absorption. Based on the Noyes-Whitney 
equation, many factors can affect a drug’s dissolution rate (Healy 1984; Frenning and 
Stromme 2003): 
 ( )sA DDR C Ch
⋅
= −    (6) 
Where DR is the dissolution rate, A is the surface area available for dissolution, D is the 
diffusion coefficient of the drug, h is the thickness of the boundary diffusion layer adjacent 
to the dissolving drug surface, Cs, is the saturation solubility of the drug in the diffusion 
layer, C is the concentration of the drug in the bulk solution at time t. As shown in the 
equation above, the drug dissolution rate is directly proportional to the surface area of the 
drug particle, which in turn is increased with decreasing particle size. This can be 
accomplished by micronization or by the use of nanosuspension to reduce the particle size 
of the drug and therefore increases drug dissolution rate, which usually is associated with 
an increase in the extent as well as rate of oral absorption (Chaumeil 1998; Li et al. 2005; 
Borm et al. 2006). Examples on a drug for which reducing its particle size had significant 
impact on its dissolution rate is griseofulvin. This molecule has a particularly low solubility 
and was thus studied as a micronized powder with a median particle size of 3 µM (Nystrom 
et al. 1985; Nystrom and Bisrat 1986). Measurement of the amount dissolved in water versus 
time using a micronized powder showed that the rate of dissolution depended on the area 
of contact, which is related to the particle size. Increasing this area was an effective way of 
increasing the rate of dissolution of this drug (Sjökvist et al. 1989).  
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Fig. 1. Relationship between number of violations of rule-offive and bioavailability and 
individual processes. “n” is the number of compounds in each bin (Varma et al. 2010). 
5.3.2 Salt form 
As noted above, many drug molecules can be classified as either weak acids or bases that 
tend to form strong ionic interaction with an oppositely charged counter-ion and maintain 
that interaction through crystallization. The resulting solid comprises charged drug 
molecules and their associated oppositely charged counter-ions and is usually referred to as 
salt. The use of salt forms as active pharmaceutical ingredients is well established in the 
literature (Berge et al. 1977; Chowhan 1978). A salt form of a drug molecule changes the 
coulombic attraction between the drug molecule and its counterion and alters the potential 
energy of the solid state. This is usually associated with alteration of the pH of the diffusion 
layer at the surface of the dissolving solid, and therefore significantly increases the solubility 
of the parent drug molecule (Cs), in that layer over its inherent solubility at the pH of the 
dissolution medium (C). In general, these changes can result in a significant increase in the 
dissolution rates and higher apparent solubility of the drug molecules in physiologically 
relevant timescales. Overall, if other relevant factors such as chemical stability, permeability, 
intestinal and liver metabolism remain constant, the dissolution rate of a compound should 
determine the rate of build-up of blood levels with time and the maximal levels achieved 
(Nelson 1957; Chowhan 1978; Hendriksen et al. 2003; Huang and Tong 2004; Li et al. 2005).  
In summary, the drug salt form usually alters the drug dissolution rate by modifying the 
diffusion layer pH at the surface of the dissolving solid (Nelson 1957). Nelson was the first 
to report this phenomenon in which the salts of acidic theophylline with high diffusion layer 
pH’s had greater in vitro dissolution rates than those exhibiting a lower diffusion layer pH. 
In fact, the rank order of dissolution rates of theophylline was closely correlated with the 
clinical blood exposure. This report led many additional studies that demonstrated the 
influence of the salt form on drug dissolution and the benefit of changing nonionized drug 
to salts (Nelson 1957; Nelson 1958; Berge et al. 1977; Nang et al. 1977; Chowhan 1978; Chen 
et al. 2002; Hendriksen et al. 2003; Huang and Tong 2004; Strickley 2004; Li et al. 2005) 
www.intechopen.com
 
Topics on Drug Metabolism 
 
18
5.3.3 Polymorphism and drug amorphous form 
Polymorphs of a drug substance are chemically identical. However, due to the differences in 
their molecular packing, they have different physical properties such as crystal shape, 
molecular density, melting temperature, hygroscopicity, and enthalpy of fusion (Huang and 
Tong 2004; Li et al. 2005). Albeit these differences, the various polymorphs tend to have 
comparable solubility profile. Pudipeddi and Serajuddin evaluated the effect of various 
polymorphs of drug molecules reported in the literature on their solubility profiles. The 
group reported that the solubility values of various polymorphs for these drug molecules 
did not differ more than two-folds. This difference  in the solubility value is not expected to 
have profound impact on the compound biopharmaceutical profile depending on the doses 
used, particle sizes, and solubility values (Pudipeddi and Serajuddin 2005). However, 
polymorphism may influence the physical and chemical stability of various drug molecules 
by influencing the rate and mechanism of decay (Cohen and Green 1973; Matsuda et al. 
1993; Singhal and Curatolo 2004). Examples are carbamezepine (Matsuda et al. 1993),  
indomethacin (Chen et al. 2002), furosemide (De Villiers et al. 1992), and enalapril maleate 
(Cohen and Green 1973; Eyjolfsson 2002).  
There are significant differences between crystalline polymorphs and the amorphous form 
of a drug. In general, the amorphous form tends to have significantly higher dissolution rate 
and solubility compared to their crystalline forms, which may significantly increase their 
rate and extent of oral absorption. However, the amorphous form is generally less 
chemically stable due to the lack of a three dimensional crystalline lattice, higher free 
volume, and greater molecular mobility. The chemical stability of amorphous systems has 
been discussed in detail elsewhere (Craig et al. 1999; Doelker 2002; Kaushal et al. 2004; 
Singhal and Curatolo 2004).  
5.3.4 Drug complexation 
The drug complexes of interest are generally divided into two major categories based on the 
energy of attraction between the components of the complexes. They are (1) covalently 
linked complexes, (2) ionic/inclusion complexes. It is interesting to note that the energy of 
attraction of covalently linked complexes is about 100 kcal/mol. Whereas; the latter type of 
complexes is less than 10 kcal/mol. Examples on covalently linked complexes are prodrugs 
that are prepared by chemical modification of the drug through the addition of a labile 
moiety, such as ester group (Van Gelder et al. 2000). This approach is widely used to 
increase drug solubility/permeability and thus improving drug bioavailability. The labile 
groups are usually broken by enzymatic action, and the parent drug is freed to produce its 
pharmacological action. The prodrug approach has been widely used in the development of 
bacampicillin, chloramphenicol, pivampicillin, and enalapril (Van Gelder et al. 2000; van De 
Waterbeemd et al. 2001; Beaumont et al. 2003).  
Inclusion compounds, which form the second category of complexes, result more from the 
architecture of molecules than from their chemical interaction. One of the constituents of the 
complex is trapped in the cage-like molecular structure of the other to yield a stable 
arrangement. Cyclodextrins have been most widely used for this purpose, since they can 
trap lipophilic drugs in their molecular envelope and form a complex having a 
comparatively more hydrophilic character (Shimpi et al. 2005). It is well established in the 
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literature that a complex formation of a drug with cyclodextrin is known to improve drug 
solubility or dissolution rate, and thereby its oral bioavailability (Irie and Uekama 1997; 
Loftsson et al. 2002; Strickley 2004; Shimpi et al. 2005). 
It should be stressed that the drug molecules can also form complexes that may adversely 
affect their oral bioavailability. One widely reported example is the complexation of 
tetracycline with aluminum, calcium, or magnesium ions to form an insoluble complex that 
cannot be absorbed (Kakemi et al. 1968; Kakemi et al. 1968). Before the complexation 
phenomenon was known, the administration of antacids with tetracycline was suggested to 
minimize the gastrointestinal disturbance (nausea and vomiting) caused by the antibiotic 
(Gugler and Allgayer 1990). As most antacids contain aluminum or magnesium hydroxide 
and/or calcium carbonate ions, such coadministration have reduced greatly the 
bioavailability of the antibiotic. However, complexation can also arise due to the calcium 
ions present in milk and other dairy products (Jung et al. 1997). For example, for 
democycline, only 13% was absorbed when administered with milk. Doxycycline has been 
reported to be less prone to complexation with dairy products, yet only 10% was absorbed 
when coadministered with aluminum hydroxide gel (Gugler and Allgayer 1990).  
6. BCS and BDDCS 
Solubility and permeability are the fundamental properties determining the bioavailability of 
an orally active drug. Based on these properties Amidon et al. proposed biopharmaceutic 
classification system (BCS), which in present times is serving as a guide for regulatory and 
industrial purposes (Amidon et al. 1995). This concept exploring dose number, dissolution 
number, and absorption number of an orally administered drug clearly dictate its systemic 
availability. These three numbers are associated with a number of multifaceted hurdles, which 
include (i) physicochemical properties of the molecule (solubility/dissolution) (ii) stability of 
drug in GI environment (acid degradation) (iii) enzymatic stability in GI lumen, epithelium 
and liver (iv) permeability (molecular weight, log P, H-bonding efficiency) and (v) substrates 
specificity to various uptake and efflux transporters. The US FDA, other regulatory agencies, 
and healthcare organizations have implemented the BCS to enable the use of in vitro solubility 
and permeability data to waive conducting expensive bioequivalence clinical studies (BE)  of 
high solubility-high permeability (Class I) drugs. While the pharmaceutical industry has taken 
advantage of BCS-based biowaivers, its principles are used throughout the drug discovery and 
development to drive oral active programs. On the basis of the apparent correlation between 
intestinal permeability rate and extent of drug metabolism, Benet and coworkers proposed 
biopharmaceutics drug disposition classification system (BDDCS), and suggested that the 
extent of drug metabolism may be used for characterizing high intestinal permeability drugs 
(Wu and Benet 2005; Benet 2009). 
7. Intestinal metabolism 
Small intestine has an ability to metabolize drugs by several pathways involving both phase 
I and phase II reactions and may lead to limited oral bioavailability. CYP3A4, the most 
abundant cytochrome P450 present in human hepatocytes and intestinal enterocytes is 
implicated in the metabolic elimination of many drugs (Paine et al. 2006; Thummel 2007). It 
has also been proposed that drug interactions involving CYP3A inhibition and induction 
may be largely occurring at the level of the intestine (Hebert et al. 1992; van Waterschoot et 
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al. 2009). In a recent analysis of 309 drugs with intravenous and oral clinical 
pharmacokinetic data, we noted that roughly 30% of the drugs in the data set show more 
than 20% intestinal extraction, underscoring the importance of considering intestinal 
metabolism in predicting bioavailability and dose projections in drug discovery and 
development settings (Varma et al. 2010). Although, the average human intestinal content of 
CYP3A has been estimated to be only about 1% of the average hepatic content (Paine et al. 
2006), the data set indicated that intestinal metabolism may contribute to first-pass 
extraction more than the hepatic metabolism for certain drugs. This could be a result of 
better access to the enzymes in the enterocytes; a function of transcellular flux and the large 
absorptive area, and/or due to reduced access to hepatic enzymes because of potential 
plasma protein binding (Thummel 2007).  
The intestinal first-pass metabolism in humans is indirectly estimated under certain 
assumption, by comparing the plasma AUCs following intravenous and oral dosing. Early 
studies in liver transplant patients during the anhepatic phase indicated the relative 
importance of the gut extraction to the first-pass metabolism for drugs such as midazolam 
and cyclosporine (Paine et al. 1996). Further clinical evidences were obtained in the grape-
fruit juice interaction studies, where coadministration of grape-fruit juice result in the 
inhibition of gut CYP3A4 without significantly affecting the hepatic metabolism of drugs 
like felodipine (Gertz et al. 2008). However, assessment of the quantitative contribution of 
intestinal and hepatic extraction in first-pass metabolism is limited by ethical and technical 
challenges. There exist gaps in predicting the gut extraction before the clinical development 
stage due to shortcomings in the in vitro-in vivo extrapolation (Eg. utilizing human intestinal 
microsomal stability). Also species differences exist where rat and monkey typically under-
predicts the fraction escaping gut extraction (Fg) in human (Cao et al. 2006; Nishimuta et al. 
2010). Recently, transgenic mice model with constitutive expression of human CYP3A4 in 
liver or intestine that provides quantitative estimation of the contribution of hepatic and gut 
extraction to the first-pass metabolism has been generated (van Waterschoot et al. 2009). 
Overall, due to limited access to the sophisticated models and complexities with in vitro in 
vivo extrapolation and species differences, intestinal metabolic disposition is far from 
consistently predictable. 
Recent studies demonstrated that efflux transporters present on the apical membrane of 
enterocytes, in particular Pgp, can affect the intestinal metabolism by prolonging the 
enterocytic transit time and consequent exposure to CYP3A enzymes (Wacher et al. 2001). A 
significant overlap has also been identified between substrates and inhibitors of CYP3A4 
and Pgp, suggesting that these two proteins may act complementarily in further limiting Fg 
of CYP3A substrates. Due to the complexity in these biochemical processes and the lack of 
availability of extensive experimental models, application of physiologically-based 
pharmacokinetic (PBPK) models and systems biology seem to provide quantitative 
prediction of first-pass metabolism. These emerging tools aim towards appropriate 
reconstruction of the physicochemical, anatomical and biochemical complexities in 
mathematical terms.  
8. Conclusions 
Reliable delivery of drugs via oral administration is most sort after in drug industry. 
Consequently, the design and development of  orally active drugs has to take into account a 
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plethora of factors which may include the physicochemical, biopharmaceutical and 
physiological determinants. While, solubility and permeability, are fundamental 
biopharmaceutical parameters that determine the oral absorption, physicochemical and 
drug substance properties are directly or indirectly associated with these parameters. 
Lipophilicity, hydrogen bonding ability and number of rotatable bonds are generally 
identified as critical molecular properties of drugs influencing the rate of membrane 
transport and thus the intestinal absorption (Fa). However, for drugs with low membrane 
permeability, role of uptake and efflux transporters may become significant and thus need 
appropriate characterization. It is believed that targeting intestinal uptake transporter and 
circumventing efflux transporters may be an useful strategy to design drugs with oral 
activity.  Understanding the contribution of intestinal metabolism to the oral bioavailability 
is also key in projecting clinical pharmacokinetics and doses. Modeling intestinal absorption 
and metabolism is complicated due to variability in the physiology and gradient enzyme 
and transporter localization. Nevertheless, better characterization of factors influencing 
intestinal absorption and metabolism might result in improved pharmacokinetic 
optimization in discovery and development settings. 
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